Gameto Raises $23M in Funding


Gameto, a NYC- and Boston, MA-based biotechnology startup solving the problem of accelerated ovarian aging to change the trajectory of women’s health and equality, raised a $20m Series A funding.

The round was led by Future Ventures, with participation from Bold Capital Partners, Lux Capital, Plum Alley, TA Ventures, Overwater Ventures, Robert Nelsen and Anne Wojcicki. Gameto also raised $3m in Seed funding in March 2020 from a range of notable investors including Jack Abraham, SALT Fund, FJ Labs, Dan Rose and Brian Armstrong.

Led by Dr. Dina Radenkovic, CEO, and Martin Varsavsky, Chairman, Gameto is building a platform for ovarian therapeutics to initially address menopause and improve assisted fertility with three sequenced programs:

  1. Fertilo – To improve assisted fertility and with the mission to eliminate infertility over time for all women.
  2. Deovo – To initiate drug discovery and a computational platform for ovarian aging.
  3. Ameno – Aiming to make the medical burden of menopause optional.